Bruker (BRKR)
Nasdaq Market Closed
Bruker Corporation is a US-listed scientific instruments and diagnostics company serving research, industrial, pharmaceutical, biotechnology, and applied laboratory markets. Its systems are used to analyse materials and biological samples at molecular, cellular, and structural levels, supporting work in areas such as drug discovery, proteomics, clinical research, nanotechnology, and advanced materials.
The company is best known for high-performance analytical platforms, including nuclear magnetic resonance and magnetic resonance systems, mass spectrometry, infrared and Raman spectroscopy, X-ray analysis tools, fluorescence microscopy, and surface metrology products. These instruments are typically sold to universities, government laboratories, hospitals, contract research organisations, and industrial customers that require precise measurement and imaging capabilities.
Bruker reports through several businesses within Bruker Scientific Instruments, including BioSpin, CALID, and Nano, as well as Bruker Energy & Supercon Technologies. CALID, which includes life science mass spectrometry and applied analysis products, is a major revenue contributor. BioSpin focuses on magnetic resonance technologies, while Nano covers advanced microscopy, X-ray, and nanoanalysis tools. BEST supplies superconducting materials and related components used in scientific and medical technologies.
The company competes in markets where performance, reliability, software, and application support are important purchasing factors. Its installed base can generate recurring revenue through service, consumables, upgrades, and software. Bruker has a global footprint, with the United States representing a key market, and it benefits from long-term demand for more sophisticated laboratory workflows across life sciences, diagnostics, semiconductor research, materials science, and environmental testing.
Last updated
- Market Cap
- 9.13B
- P/E
- —
- P/FCF
- 416.85
- P/S
- 2.64
- Enterprise Value
- 10.67B
- Sector
- —
- Industry
- Laboratory Analytical Instruments
- Address
- 40 MANNING RD, BILLERICA, MA, 01821
Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Biognosys to Launch Metabolomics/Lipidomics Services for Multiomics Drug Discovery and Clinical Research
NMR Spectroscopy Market to Hit USD 2.08 Billion by 2032, Fueled by Pharmaceutical R&D and Rising Demand for Molecular Structure Analysis | SNS Insider
IR Spectroscopy Market to surpass USD 2 billion by 2032, Says Global Market Insights inc.
Biognosys präsentiert auf dem HUPO World Congress wichtige Innovationen aus dem gesamten Spektrum der Proteomik-Forschungsanwendungen
Transforming Healthcare From The Inside Out, Nanorobots Are Revolutionizing Treatment With Precision At The Nanoscale: A Report by TNR, The Niche Research
U.S. Multiomics Market Trends Analysis Report 2024-2030: Increasing Demand for Personalized Medicines, Growing Prevalence of Chronic Diseases, and Rising Application in Drug Discovery & Development
Chemical, Biological, Radiological, and Nuclear (CBRN) Security Market to Reach $29.9 Billion, Globally, by 2033 at 5.1% CAGR: Allied Market Research
Nanobots in Healthcare Research Report 2024: A $7.1 Billion Market in 2023 - Global Forecast to 2030 - Revolutionizing Healthcare with Targeted Drug Delivery and Minimally Invasive Surgeries
Multiphoton Microscopy Market Sales to Surge at 5.5% CAGR, Reaching US$ 339.7 Million by 2034 | Fact.MR
Soil Testing Equipment Market Size to Reach USD 5.5 Billion By 2033, at 5.3% CAGR: Insights by Dimension Market Research
IR Spectroscopy Market Expected to Reach USD 0.904 Billion by 2032, Driven By Increasing Healthcare Institutions and Clinical Research Centers: SNS Insider
Global Process Analytical Technology Market Size To Worth USD 14.15 Billion by 2033 | CAGR of 6.54%
Europe, CIS & Africa Spatial Transcriptomics (Instruments, Consumables) Market Size, Share & Trends Analysis Report 2024-2030
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
Zacks Industry Outlook Mettler-Toledo and Bruker
Antimicrobial Resistance Surveillance Market Size to Hit - GlobeNewswire
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab - Zacks Investment Research
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 9.13B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 10.67B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.7
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.64
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 27.66
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.08
- EPS
- -0.24
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.48%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 416.85
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 65.07
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 21.9M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -1.48%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -0.59%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.68
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.55
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.72
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.1
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.79M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 59.97
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 823.4M | 977.2M | 860.5M | 797.4M | 801.4M |
| Gross profit | 379.8M | 449.2M | 379.4M | 357.9M | 391.2M |
| Operating income | 10.2M | 76.3M | -51.8M | 11.9M | 31.8M |
| EBITDA | 68.5M | 134.4M | 100.4M | 82.4M | 82.2M |
| Net income | 3.5M | 14.9M | -62.4M | 7.6M | 17.4M |
| Basic EPS | 0.02 | 0.1 | -0.41 | 0.05 | 0.11 |
| Diluted EPS | 0.02 | 0.1 | -0.41 | 0.05 | 0.11 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 6.13B | 6.24B | 6.43B | 6.34B | 5.93B |
| Total liabilities | 3.63B | 3.73B | 3.94B | 4.47B | 4.08B |
| Total equity | 2.47B | 2.47B | 2.45B | 1.82B | 1.83B |
| Cash & equivalents | 133.4M | 298.8M | 293.1M | 92M | 184.2M |
| Current assets | 2.1B | 2.21B | 2.35B | 2.16B | 2.11B |
| Current liabilities | 1.36B | 1.28B | 1.27B | 1.35B | 1.34B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 71.2M | 229.8M | -33.2M | -127.5M | 65M |
| Investing cash flow | -39.7M | -55.5M | -23.8M | -91.1M | -26.1M |
| Financing cash flow | -204.9M | -167.6M | 258.4M | 95.5M | -51.2M |
| Change in cash | -165.5M | 5.8M | 201.1M | -91.5M | 1M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K/A — BRUKER CORP | View Filing | |
| edgar index | SD — BRUKER CORP | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| edgar index | 144 — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Bernard Thierry | View Filing | |
| edgar index | 10-Q — BRUKER CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 144 — BRUKER CORP | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| edgar index | DEF 14A — BRUKER CORP | View Filing | |
| edgar index | DEFA14A — BRUKER CORP | View Filing | |
| edgar index | ARS — BRUKER CORP | View Filing | |
| edgar index | 3 — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 144 — BRUKER CORP | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| edgar index | 10-K — BRUKER CORP | View Filing | |
| edgar index | S-8 — BRUKER CORP | View Filing | |
| edgar index | S-8 POS — BRUKER CORP | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | 4 — BRUKER CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — BRUKER CORP | View Filing | |
| form 4 | Form 4 — FRANCIS LAURA | View Filing | |
| form 4 | Form 4 — ORNELL JOHN A | View Filing | |
| form 4 | Form 4 — ROSENTHAL BOB | View Filing | |
| form 4 | Form 4 — PACKER RICHARD A | View Filing | |
| form 4 | Form 4 — LINTON WILLIAM A | View Filing | |
| form 4 | Form 4 — Perkins Adelene Q | View Filing | |
| form 4 | Form 4 — Anderson Bonnie H | View Filing | |
| form 4 | Form 4 — Requardt Hermann Fritz | View Filing | |
| form 4 | Form 4 — Friend Cynthia M | View Filing | |
| form 4 | Form 4 — Phillips Jack | View Filing | |
| form 4 | Form 4 — Bures Thomas | View Filing | |
| edgar index | 144 — BRUKER CORP | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| form 4 | Form 4 — Munch Mark | View Filing | |
| edgar index | 8-K — BRUKER CORP | View Filing |